Recent News

• 05.08.2025 - Cassava Reports Q1 2025 Financials Results, Provides Business Update
• 05.01.2025 - Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC
• 04.30.2025 - Jack Moore, PhD
• 04.21.2025 - Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development
• 04.21.2025 - Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development
• 03.25.2025 - Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data
• 03.25.2025 - Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data
• 03.03.2025 - Cassava Sciences Reports 2024 Financial Results and Provides Business Update

Recent Filings

• 04.21.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.21.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.21.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.21.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.21.2025 - EX-99.1 EX-99.1
• 04.21.2025 - 8-K Current report
• 04.14.2025 - ARS Annual Report to Security Holders
• 04.14.2025 - DEF 14A Other definitive proxy statements
• 04.03.2025 - PRE 14A Other preliminary proxy statements
• 03.25.2025 - EX-99.1 EX-99.1